|Last Price||Today's Change||52-Week Range||Trading Volume|
|57.61||0.73 (+1.28%)||52.49 - 63.62||10.0 million (Below Avg)|
Market data as of 4:03PM 04/20/15. Quotes are delayed by at least 15 min.
KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy...
04/19/2015 8:30 AM ET